Medicare Negotiated Drugs Can Face Immediate Generic, Biosimilar Substitution, CMS Proposal Confirms

 
• By Cathy Kelly

Stelara, Xarelto, Januvia and Farxiga, which are expected to have biosimilar or generic competition before the end of 2026, could be the first negotiated drugs subject to the policy.

Policy aims to help promote generic, biosimilar uptake in Part D (Shutterstock)

More from Regulation

More from Generics Bulletin